Disease-Modifying Treatment Options in Very Early Onset Multiple Sclerosis-What Choices Are There for Onset Under 5 Years of Age? A Systematic Review
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Early treatment with high-efficiency disease-modifying therapies (DMTs) is crucial for very early pediatric-onset multiple sclerosis (POMS) before age five. Prompt intervention may improve prognosis and recovery, leveraging neuroplasticity in young children.
Area Of Science
- Pediatric Neurology
- Neuroimmunology
- Clinical Research
Background
- Very early pediatric-onset multiple sclerosis (POMS) with onset before age five is rare.
- Limited clinical studies exist for this age group, leading to off-label treatment decisions.
- Clinicians face challenges managing POMS due to a lack of age-specific treatment guidelines.
Purpose Of The Study
- To review existing literature on very early POMS (onset before age 5).
- To analyze clinical, treatment, and outcome characteristics of patients with very early POMS.
- To evaluate the efficacy of disease-modifying treatments (DMTs) in this population.
Main Methods
- A comprehensive literature review was conducted from 1982 to 2025.
- Data from 101 patients with very early POMS were analyzed.
- Statistical analysis included descriptive statistics and cohort-level estimates, with GenAI-assisted verification.
Main Results
- At onset, symptoms included ataxic syndrome (57.4%), pyramidal syndrome (41.4%), and ophthalmoplegia (10.3%).
- 22.7% of patients developed seizures, and half remained untreated.
- Among treated patients, high-efficacy DMTs like Natalizumab showed promising outcomes in a case study.
Conclusions
- Early initiation of high-efficiency DMTs should be considered for very early POMS.
- Harnessing neuroplasticity in young children may enhance recovery from acquired disability.
- Aggressive treatment strategies may improve long-term prognosis for POMS.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...